Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
Authors
Keywords
Immunotherapy, Lung cancer, PD-1/PD-L1, Switch/sucrose-non-fermentable (SWI/SNF), SMARCA4
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-04-30
DOI
10.1016/j.cllc.2022.03.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinicopathologic Characteristics of BRG1-Deficient NSCLC
- (2020) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
- (2019) C Henon et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report
- (2019) Tomoyuki Naito et al. Thoracic Cancer
- Thoracic SMARCA4-deficient sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
- (2019) N. Rekhtman et al. Journal of Thoracic Oncology
- Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
- (2019) Kohichi Takada et al. Thoracic Cancer
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities
- (2017) Akihiko Yoshida et al. MODERN PATHOLOGY
- SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior
- (2017) Jennifer L Sauter et al. MODERN PATHOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer
- (2015) E. H. Bell et al. CLINICAL CANCER RESEARCH
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
- (2015) Francois Le Loarer et al. NATURE GENETICS
- Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung
- (2015) Taichiro Yoshimoto et al. PATHOLOGY INTERNATIONAL
- Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
- (2014) Pilar Ramos et al. NATURE GENETICS
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features
- (2012) Daisuke Matsubara et al. CANCER SCIENCE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search